CGP 4832
CGP 4832 is a Rifamycin S (HY-125365) derivative and Antibacterial agent. CGP 4832 inhibits DNA-dependent transcription through DNA-dependent RNA polymerase. CGP 4832 exhibits activity against Gram-positive bacteria comparable to Rifampicin (HY-B0272), but is more potent against certain Gram-negative bacterial species, such as Escherichia coli ETH 2018 (MIC 0.01 µg/mL) and Salmonella AX 5 (MIC 0.5 µg/mL). CGP 4832 can be used for research on Gram-negative bacterial infections.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 113303-81-4
- 화학식: C49H65N3O15
- 분자량:936.05
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
제품 설명
IC50 & Target
[1]|
RNA Polymerase |
In Vitro
The MIC of CGP-4832 (24 h) against Escherichia coli MG1655 in iron-limited RPMI-1640 (0.25 mg/L) is 32-fold lower than that in iron-rich MHII (8 mg/L)[1].
CGP-4832 (24 h) does not show enhanced activity against Acinetobacter baumannii HUMC1 or LAC-4 in iron-limited RPMI-1640 compared with MHII, with MICs of 8 mg/L and 2 mg/L in RPMI-1640, respectively[1].
CGP 4832 (hydroquinone form; 10 min) inhibits DNA-dependent RNA polymerase from Escherichia coli ETH 2018 with ED50 values of 0.09 µg/mL and 0.06 µg/mL for crude and highly purified enzyme, respectively, and no correlation exists between MIC and enzyme inhibition among the bacterial strains tested[2].
CGP 4832 exhibits activity against Gram-positive bacteria comparable to that of Rifampicin (HY-B0272), but is 80-400 times more potent against certain Gram-negative bacterial species, such as Escherichia coli ETH 2018 (MIC 0.01 µg/mL) and Salmonella AX 5 (MIC 0.5 µg/mL)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 113303-81-4
-
분자량 936.05
-
화학식 C49H65N3O15
-
SMILES
CO[C@H]1/C=C/O[C@@]2(C)OC3=C(C4=C(C(O)=C3C)C(C(NC(/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(CC(OCC5CCCN(C)C5)=O)=O)[C@@H]1C)=O)=C(N6CCOCC6)C4=O)=O)C2=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
순도&문서
References
[1]. Lu P, et al. Defining the minimum inhibitory concentration of 22 rifamycins in iron limited, physiologic medium against Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates. PloS one. 2023;18(6):e0287102. [Content Brief]
[2]. Wehrli W, et al. CGP 4832, a new semisynthetic rifamycin derivative highly active against some gram-negative bacteria. The Journal of antibiotics. 1987 Dec;40(12):1733-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)